Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …

Background: Despite international initiatives on collaboration within the field of rare
diseases, patient access to orphan medicinal products (OMPs) and healthcare services …

Background There are concerns that high prices of cancer medicines may limit patient
access. Since information on prices for cancer medicines and their impact on affordability is …

Introduction Racial and ethnic categories are frequently used in pharmacogenetics literature
to stratify patients; however, these categories can be inconsistent across different studies. To …

Patients across Europe face inequity regarding access to anticancer medicines. While
access is typically evaluated through reimbursement status or sales data, patients can …

After the fall of communism, the healthcare systems of Central and Eastern European
countries underwent enormous transformation, resulting in departure from publicly financed …

Objective: To provide health-related quality of life (HRQoL) data to support health
technology assessment (HTA) and reimbursement decisions in Romania, by developing a …

BACKGROUND: The use of generic medicines instead of branded, is one of the main
policies to decrease the expenditures and provide access to affordable and essential …

Community pharmacists are essential front-line health workers, involved in relieving the
COVID-19 burden. Their health-related quality of life status needs to be assessed, as lower …

Introduction: The significant therapeutic potential of the advanced therapies (ATs) has
predetermined the increased interests in their development mainly in the context of rare …